Umoja Biopharma
In vivo CAR-T company using lentiviral vectors (VivoVec); first CD22-directed in vivo CAR-T cleared for US trials in 2026.
UB-VV111 (CD19) and UB-VV400 (CD22, IND cleared 2026) generate CAR-T cells in situ for relapsed/refractory B-cell malignancies; UB-VV111 holds Fast Track designations. First clinical data from an investigator-initiated UB-VV400 trial in China expected in the second half of 2026.
Pages like this
not linked directly; found by shared links- CompanyInterius BioTherapeutics
Shares In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T, Manufacturing cost and time for living and radioactive medicines and the tag frontier.
- CompanyOrna Therapeutics (Eli Lilly)
Shares In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T, CD19 and the tag frontier.
- TechnologyMetabolic therapy: starving the tumour of a nutrient
Shares Acute lymphoblastic leukaemia and the tag frontier.
- TechnologyCAR-NK & CAR-macrophage
Shares Manufacturing cost and time for living and radioactive medicines and the tag frontier.
- TechnologyTargeted alpha therapy
Shares Manufacturing cost and time for living and radioactive medicines and the tag frontier.
- TechnologyIn vivo base and prime editing for cancer
Shares In vivo CAR-T and the tag frontier.
- IdeaIn vivo CAR-T against solid-tumour antigens
Shares In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T, Manufacturing cost and time for living and radioactive medicines.
- TechnologyEngineered exosomes as drug carriers
Shares In vivo CAR-T and the tag frontier.